Loading clinical trials...
Loading clinical trials...
A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)
Conditions
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device
Placebo delivered via INOpulse DS Device
+1 more
Locations
51
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Pulmonary Specialists
Phoenix, Arizona, United States
Allianz Research Institute, Inc.
Fountain Valley, California, United States
University of California, San Francisco-Fresno
Fresno, California, United States
West Los Angeles VA Healthcare Center
Los Angeles, California, United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Start Date
April 1, 2012
Primary Completion Date
October 1, 2014
Completion Date
July 1, 2016
Last Updated
February 27, 2023
NCT05746039
NCT07218029
NCT07073820
NCT03854071
NCT07477197
NCT06899815
Lead Sponsor
Bellerophon Pulse Technologies
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions